Active Ingredient(s):Mobocertinib FDA Approved: * September 15, 2021 Pharm Company: *TAKEDA PHARMS USA Category:Cancer
Mobocertinib, sold under the brand name Exkivity, is used for the treatment of non-small cell lung cancer.
The most common side effects include diarrhea, rash, nausea, stomatitis, vomiting, decreased appetite, paronychia, fatigue, dry skin, and musculoskeletal pain.
Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region.[...
* May have multiple approval dates, manufacturers, or labelers.